Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.44 |
| ▸ | MAP3K12 | Q12852 | 8/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021297 | 0.89 | LRRK2 (0.39) | LRRK2MAP3K12KAT2BKCNH2 | |
| SCHEMBL16985571 | 0.88 | LRRK2 (0.37) | LRRK2MAP3K12KAT2BKCNH2 | |
| SCHEMBL16985492 | 0.88 | LRRK2 (0.37) | LRRK2MAP3K12KAT2BKCNH2 | |
| SCHEMBL21850266 | 0.88 | LRRK2 (0.37) | LRRK2MAP3K12KAT2BKCNH2 | |
| SCHEMBL21850251 | 0.85 | LRRK2 (0.47) | LRRK2MAP3K12KAT2BKCNH2 | |
| SCHEMBL16975418 | 0.79 | KAT2B (0.35) | LRRK2MAP3K12KAT2BKCNH2 | |
| SCHEMBL24271370 | 0.77 | LRRK2 (0.42) | LRRK2MAP3K12KAT2BKCNH2 | |
| SCHEMBL16985433 | 0.77 | LRRK2 (0.53) | LRRK2MAP3K12KAT2BKCNH2 | |
| SCHEMBL16985407 | 0.77 | LRRK2 (0.53) | LRRK2MAP3K12KAT2BKCNH2 | |
| SCHEMBL16975542 | 0.77 | LRRK2 (0.53) | LRRK2MAP3K12KAT2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3722298-B1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC (KR) | 2023-08-02 | — | — | EP | disclosed |
| EP-3722298-B1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC (KR) | 2023-08-02 | — | — | EP | disclosed |
| CN-111433208-B | Pyrrolo (pyrazolo) pyrimidine derivatives as LRRK2 inhibitors | 奥斯考泰克公司 | 2023-06-30 | — | — | CN | disclosed |
| US-11370796-B2 | Substituted pyrazoles as LRRK2 inhibitors | OSCOTEC INC. (KR) | 2022-06-28 | — | — | US | disclosed |
| US-11370796-B2 | Substituted pyrazoles as LRRK2 inhibitors | OSCOTEC INC. (KR) | 2022-06-28 | — | — | US | disclosed |
| US-20210363144-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC. (KR) | 2021-11-25 | — | — | US | disclosed |
| US-20210363144-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC. (KR) | 2021-11-25 | — | — | US | disclosed |
| EP-3722298-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | Oscotec Inc. (KR) | 2020-10-14 | — | — | EP | disclosed |
| EP-3722298-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | Oscotec Inc. (KR) | 2020-10-14 | — | — | EP | disclosed |
| CN-111433208-A | Pyrrolo (pyrazolo) pyrimidine derivatives as L RRK2 inhibitors | 奥斯考泰克公司 | 2020-07-17 | — | — | CN | disclosed |
| WO-2019112269-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | 주식회사 오스코텍 | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363144-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | LRRK2, PARK7, WEE1 | LRRK2 1/4885MAP3K12 691/4885KAT2B 4192/4885 |
| US-11370796-B2 | Substituted pyrazoles as LRRK2 inhibitors | LRRK2, PARK7, PAK3 | LRRK2 1/4885MAP3K12 205/4885KAT2B 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.